Ionis Pharmaceuticals has forged a significant global licensing agreement with Recordati, a prominent international pharmaceutical company, granting Recordati exclusive rights…
Read More
Ionis Forecasts $2 Billion Peak Sales for Tryngolza, Leveraging First-Mover Advantage in Severe Hypertriglyceridemia
Ionis Pharmaceuticals is poised to redefine its market position with ambitious peak sales forecasts of $2 billion for its newly…
Read MoreYOU MAY HAVE MISSED
